In 252 JAK inhibitor-naïve adults with intermediate-2 or high-risk myelofibrosis, navitoclax plus ruxolitinib doubled ≥35% spleen volume reduction at week 24 vs placebo plus ruxolitinib (63.2% vs 31.5%), without improving symptom scores; grade 3/4 cytopenias were more common.
RCTn = 252
Pemmaraju et al. TRANSFORM-1 phase 3 study: efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosis